Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381215 | 0.90 | MAOB (0.44) | HSP90AB1MAOBSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL9202564 | 0.88 | HSP90AB1 (0.66) | HSP90AB1CA12CA1CA9CA2 | |
| SCHEMBL13802188 | 0.83 | HSP90AB1 (0.55) | HSP90AB1CA12CA1CA9CA2 | |
| SCHEMBL2984242 | 0.83 | HSP90AB1 (0.76) | HSP90AB1CA12CA1CA9CA2 | |
| SCHEMBL1500686 | 0.82 | MAOB (0.40) | MAOBSMN1; SMN2ALDH1A1GAALMNA | |
| SCHEMBL30739013 | 0.82 | MAOB (0.40) | MAOBSMN1; SMN2ALDH1A1GAALMNA | |
| SCHEMBL137425 | 0.80 | HSP90AB1 (0.51) | HSP90AB1MAOBCA12CA1CA9 | |
| SCHEMBL137510 | 0.80 | HSP90AB1 (0.47) | HSP90AB1CA12CA1CA9CA2 | |
| SCHEMBL27721808 | 0.79 | HSP90AB1 (0.54) | HSP90AB1CA12CA1CA9CA2 | |
| SCHEMBL24207172 | 0.77 | SMN1; SMN2 (0.42) | HSP90AB1MAOBSMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257524-B1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | BRICKELL BIOTECH INC (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2257524-B1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | BRICKELL BIOTECH INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-8362044-B2 | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362044-B2 | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362044-B2 | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2257536-A2 | CYCLIC DIARYL ETHER AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2257524-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009102893-A2 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102893-A2 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009099902-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009099902-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | HSP90AB1 2237/4885MAOB 1134/4885CA12 4750/4885 |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | HSP90AB1 2237/4885MAOB 1134/4885CA12 4750/4885 |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER1 | HSP90AB1 2978/4885MAOB 1767/4885CA12 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.